Hydromorphone Hydrochloride Tablet, Extended Release
NDC Package 13811-702-10
Package Information
Hydromorphone Hydrochloride tablets is hydromorphone hydrochloride extended-release tablets are indicated in opioid-tolerant patients for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids.Patients considered opioid tolerant are those who are receiving, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid. This formulation utilizes a tablet, extended release delivery system. Marketed by Trigen Laboratories, Llc, this product is identified by NDC 13811-702 and is authorized under FDA application ANDA205629.
Identification & Billing
- RxCUI: 1306898 - HYDROmorphone HCl 32 MG 24HR Extended Release Oral Tablet
- RxCUI: 1306898 - 24 HR hydromorphone hydrochloride 32 MG Extended Release Oral Tablet
- RxCUI: 1306898 - hydromorphone hydrochloride 32 MG 24 HR Extended Release Oral Tablet
- RxCUI: 2706360 - HYDROmorphone hydrochloride 24 MG 24HR Extended Release Oral Tablet
- RxCUI: 2706360 - 24 HR hydromorphone hydrochloride 24 MG Extended Release Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 13811 - Trigen Laboratories, Llc
- 13811-702 - Hydromorphone Hydrochloride
- 13811-702-10 - 100 TABLET, EXTENDED RELEASE in 1 BOTTLE
- 13811-702 - Hydromorphone Hydrochloride
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 13811-702-10 identifies a specific commercial package of 100 tablet, extended release in 1 bottle of Hydromorphone Hydrochloride, a human prescription drug labeled by Trigen Laboratories, Llc. This tablet, extended release is formulated for oral use and contains hydromorphone hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Trigen Laboratories, Llc on September 15, 2016. The current certification is valid through December 31, 2027.
How is this Trigen Laboratories, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 13811070210. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.